Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

1182.14.00001 Boehringer Ingelheim Investigational Site, Los Angeles

1182.14.00006 Boehringer Ingelheim Investigational Site, Los Angeles

1182.14.00010 Boehringer Ingelheim Investigational Site, Hartford

1182.14.00004 Boehringer Ingelheim Investigational Site, Chicago

1182.14.00008 Boehringer Ingelheim Investigational Site, North Worcester

1182.14.00009 Boehringer Ingelheim Investigational Site, Springfield

1182.14.00002 Boehringer Ingelheim Investigational Site, Cleveland

1182.14.00007 Boehringer Ingelheim Investigational Site, Memphis

1182.14.00003 Boehringer Ingelheim Investigational Site, Houston

1182.14.5401 Fundación Huésped, Capital Federal

1182.14.55002, São Paulo

1182.14.55003, São Paulo

1182.14.11002 Boehringer Ingelheim Investigational Site, Toronto

1182.14.11001 Boehringer Ingelheim Investigational Site, Montreal

1182.14.33004 Boehringer Ingelheim Investigational Site, Lyon

1182.14.33005 Boehringer Ingelheim Investigational Site, Nantes

1182.14.33001 Boehringer Ingelheim Investigational Site, Paris

1182.14.33002 Boehringer Ingelheim Investigational Site, Paris

1182.14.33003 Boehringer Ingelheim Investigational Site, Paris

1182.14.33006 Boehringer Ingelheim Investigational Site, Paris

1182.14.49002 Boehringer Ingelheim Investigational Site, Berlin

1182.14.49001 Boehringer Ingelheim Investigational Site, Frankfurt am Main

1182.14.49004 Boehringer Ingelheim Investigational Site, München

1182.14.39001 Boehringer Ingelheim Investigational Site, Padua

1182.14.39003 Boehringer Ingelheim Investigational Site, Roma

1182.14.52001 CLINDI (Clínica de Inmunodeficiencias), México, D.F.

1182.14.52002, México, D.F.

1182.14.00005 Boehringer Ingelheim Investigational Site, San Juan

1182.14.34002 Boehringer Ingelheim Investigational Site, Barcelona

1182.14.34001 Boehringer Ingelheim Investigational Site, Madrid